Tiziana Life Sciences (TILS)

 

TILS Share PerformanceMore

52 week high240.00 25/04/17
52 week low102.05 08/06/17
52 week change -33.50 (-17.27%)
4 week volume162,852 26/07/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Tiziana converts loan notes to shares

Tiziana Life Sciences, a clinical stage biotechnology company, said holders of the company's convertible loan note (CLN) h...

Conversion of outstanding loan notes

Miscellaneous medium priority announcements

Publication of Research Article on Foralumab

Miscellaneous medium priority announcements

Tiziana enrols first patient in Phase IIa clinical trial

Tiziana Life Sciences announced the enrolment of the first patient in its Phase IIa clinical trial with milciclib, a novel inhib...

Initiation of a Phase IIa Clinical Trial

Application by a company to a regulatory body for a product or service (e.g. approval to market a pharmaceutical product)

Proposed changes to CLNs and Warrant Terms

Miscellaneous medium priority announcements

Result of AGM

Notification of the result of any voting at an AGM

Appointment of Dr Kunwar Shailubhai as CEO

Miscellaneous medium priority announcements

Fundamental DataMore

EPS-7.7
Dividend yield0 %

Equity Research (TILS)

equity development
Tiziana Life Sciences PLC
26/01/2015
TILS has just announced an exclusive license with Nerviano Medical Sciences (NMS) for its Phase 2 anti-cancer drug candidate, milciclib. It helps block the rampant cell division associated with...
equity development
Tiziana Life Sciences PLC
12/01/2015
Tiziana (TILS) and Novimmune S.A., a company focused on the discovery and development of antibody-based drugs to benefit patients with inflammatory, auto-immune disorders, and cancer, have announced...
equity development
Tiziana Life Sciences PLC
30/09/2014
Tiziana Life Sciences (TILS) has identified a potential 'master regulator' for metastatic breast cancer (mBC). 'Bcl-3 inhibition' would be a novel strategy for treatment,...

Latest discussion posts More

  • Top up

    Bad news this am but couldn't resist a 500 top up at 115.06.
    8-Jun-2017
    osammyboy
  • Fundraise

    Beaufort Securities's note out this morning on Research Tree: "Tiziana progressed well during the FY2015. It strengthened its portfolio by acquiring exclusive licence for both ...
    8-Jun-2016
    Simbr
  • no buying

    With sp @110 and bid @ 115 I tried buying 2500 online at Barclays. Quoted 187.4 Obviously buying is being discouraged for whatever reason
    28-Apr-2016
    osammyboy

Users' HoldingsMore

Users who hold Tiziana Life Sciences also hold..
ID:ISIN:GB00B474YB1263%
LLOYDS GRP.29%
ROYAL BANK SCOT20%
TAYLOR WIMPEY15%
BARCLAYS13%

Codes & Symbols

ISINGB00BKWNZY55
SymbolsTILS, LSE:TILS, TILS.L, TILS:LN, LON:TILS, XLON:TILS